hVIVO (LON:HVO) Stock Jumps 11.7% – Time to Buy?

hVIVO plc (LON:HVO) shares shot up 11.7% during mid-day trading on Thursday. The stock traded as high as GBX 6.30 and last traded at GBX 6.20. 2,113,626 shares changed hands during mid-day trading, a decline of 10% from the average session volume of 2,346,297 shares. The stock had previously closed at GBX 5.55.

Analyst Upgrades and Downgrades

Separately, Peel Hunt reissued a “buy” rating and issued a GBX 14 price objective on shares of hVIVO in a research note on Monday, October 12th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 16.33.

hVIVO Trading Down 3.3%

The company has a debt-to-equity ratio of 43.38, a current ratio of 1.21 and a quick ratio of 1.16. The stock has a market cap of £39.96 million, a P/E ratio of -3.26 and a beta of 1.66. The firm’s 50 day moving average price is GBX 6.17 and its 200-day moving average price is GBX 7.11.

hVIVO (LON:HVO) last issued its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.82) earnings per share (EPS) for the quarter. hVIVO had a negative return on equity of 35.13% and a negative net margin of 31.76%. As a group, equities research analysts forecast that hVIVO plc will post 1.55 earnings per share for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.